KemPharm, Inc. (KMPH) News
Filter KMPH News Items
KMPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest KMPH News From Around the Web
Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.
KemPharm selects KP1077 for idiopathic hypersomnia as lead SDX candidateKemPharm (KMPH) has added ~3.9% in the post-market after announcing the selection of KP1077 for idiopathic hypersomnia ((IH)) as its lead serdexmethylphenidate ((SDX)) candidate in |
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development StrategyKemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and Revenues Extend Cash Runway through 2025 and Beyond AZSTARYS® National Launch Accelerating, Full Sales Team in Place by end of January 2022 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, January 19, 2022, at 4:30 p.m. ET CELEBRATION, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) - |
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline ExpansionConference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19, 2022, at 4:30 p.m. ET, to discuss the Company’s strategy for advancing and expandi |
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual ConferenceData highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that research involving serdexmethylphenidate (SDX), the company’s proprietary prodrug of d-methylphenidate (d-MPH), will be featured in two poster presentati |
KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022. Details of the events are as follows: Event: BIO Partnering @ JPMDate: January 10-14, 2022Registration: https://www.bio.org/events/bio-partnering-j |
Implied Volatility Surging for KemPharm (KMPH) Stock OptionsInvestors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately. |
Insider Trading At KemPharm Inc. (NASDAQ: KMPH): What Did We Note?KemPharm Inc. (NASDAQ:KMPH) traded at $8.31 at close of the session on Monday, 12/20/21, made an upward move of 6.81% on its previous days price. Looking at the stock we see that its previous close was $7.78 and the beta (5Y monthly) reads 3.21 with the days price range being $7.66 $8.91. In terms Insider Trading At KemPharm Inc. (NASDAQ: KMPH): What Did We Note? Read More » |
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase ProgramCELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its Board of Directors has authorized a program to repurchase up to $50 million of the Company’s outstanding stock. The share repurchase authorization is effective immediately and valid through December 31, 2023. This program is equivalent to approximately 18 percent of KemPharm’s current market |
Kempharm added to Nasdaq Biotechnology indexNo summary available. |
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of Higher-Dose SDXData reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS ® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects |